



TVM | Capital
Winter Conference 2015

Speaker/Moderator Profiles

(In order of appearance)

Wednesday, Feb 11

2:00pm Welcome Address



Hubert Birner

Managing Partner

TVM Capital Life Science Montreal & Munich

Dr. Birner is responsible for TVM Capital Life Sciences' overall investment strategy and the fund operations in North America and Europe.

Dr. Birner joined TVM Capital in 2000 as an investment manager. He is responsible for numerous active investments in Europe as well as the United States. He currently serves as Chairman of the Board of Argos Therapeutics Inc. (Durham, North Carolina) and is a member of the Board of Directors of Proteon Therapeutics, Inc (Kansas City, Missouri) and Probiodrug (Halle, Germany). Over many years, he was the Chairman/Vice Chairman of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany) which were acquired in 2008 by Bayer HealthCare AG and Shire Ltd. respectively.

Before joining TVM Capital, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca. Hubert joined Zeneca from McKinsey & Company's European Health Care and Pharmaceutical practice. As a management consultant, he gained extensive experience in R&D management; marketing and sales; and joint venture structuring and business development. Dr. Birner was also an Assistant Professor for biochemistry at the Ludwig-Maximilian-University in Munich. In this capacity, he directed various research projects for large pharmaceutical companies. Dr. Birner holds an MBA from Harvard Business School and a doctoral degree in biochemistry from Ludwig-Maximilian-University Munich, where he graduated summa cum laude. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases.

2:15pm Update on TVM Capital Venture



Luc Marengere

Managing Partner

TVM Capital Venture Montreal

Dr. Marengere oversees the establishment of the new Canadian operations and the North American investment strategy as well as deal sourcing and execution.

Dr. Marengere joins TVM Capital after more than 15 years of venture capital experience in Canada and the U.S. Most recently, Dr. Marengere was a Managing General Partner with VG Partners where he successfully launched and oversaw the operations and investments of the VG Advanced Life Sciences Fund (VG ALSF).

Luc was a Director on the Boards of Trillium Technologies Inc., (Toronto, ON); Cytochroma Inc., (Toronto, ON); Aegera Therapeutics, Inc. (Montréal, QC); Cita Neuropharma (sold to Vernalis Plc, UK), (Toronto, ON) and lastly Argos Therapeutics Inc., (Durham, NC). Luc also invested in VisualSonics, Inc. (sold to U.S.-based SonoSite), (Toronto, ON). Prior to joining VG Partners, he focused on making venture investments in the life science sector while with CDP Capital – Technology Ventures and MDS Capital Corp.

Prior to his venture capital career, he conducted commercially-oriented research in the fields of immunology and oncology while at Amgen. He holds a Ph.D. from University of Toronto's department of Medical Biophysics and Molecular Genetics.



TVM | Capital
Winter Conference 2015

2:30pm Panel discussion - TVM LS VII- New Deals & Progress Updates

Panelists:

- **Wolfgang Beier**, leon-nanodrugs GmbH
- **Cameron Black**, Kaneq Bioscience Ltd.
- **Thomas P. Mathers**, CoLucid Pharmaceuticals, Inc.
- **Gary Muirhead**, Ixchelsis Ltd.

Moderator: Cynthia Lavoie, TVM Capital Life Science Montreal



Cynthia Lavoie

General Partner

TVM Capital Life Science Montreal

Dr. Lavoie is responsible for deal making, deal origination and execution and for the management of portfolio companies in the US and Canada. Dr. Lavoie has led investments into Montreal-based companies Kaneq Bioscience and FAAH Pharma, where she serves on the Board of Directors. Dr. Lavoie also serves on the board of Anchor Therapeutics, located in Cambridge, MA. Dr. Lavoie joined the firm in 2012 with ten years of investment experience and another ten years in research institutions and life science firms.

Prior to her current tenure, Dr. Lavoie was with VG Partners, a large Canadian private equity firm, where her most recent role was as Partner and head of life sciences. She has served on the boards of therapeutics and device companies Aegera Therapeutics when it was sold to Pharmascience, Cytochroma (sold to Opko Health), Interface Biologics and Trillium Therapeutics (TSX: TR), among others. Dr. Lavoie also had a direct role in the sale of VisualSonics, an imaging company, to SonoSite Inc. (now Fujifilm SonoSite). Previously, Dr. Lavoie was a marketing strategy consultant with drug/device developer Vasogen (merged with Intellipharmaceutics; NASDAQ: IPCI).

Dr. Lavoie completed her PhD at McGill University and carried out academic and commercially focused research at the University of Texas Southwestern Medical Center. Dr. Lavoie graduated with a first class honors MBA from the Rotman School of Management.



Wolfgang Beier

Managing Director

leon-nanodrugs

Dr. Wolfgang Beier is the Managing- and Scientific Director of leon-nanodrugs GmbH in Munich.

He has 30 years of international R&D experience in the pharmaceutical industry and in the CRO-business.

He held senior management R&D positions in various pharma companies (Byk Gulden, Akzo Organon etc.) and he has deep experience with FDA/EMA drug approvals.

He focused on drug development in oncology and was a founder and CEO of PFK Pharma Research (CRO) and co-founder of Onocology World, Munich.



Cameron Black

Vice President, Discovery

Kaneq Pharma

Dr. Black holds a Ph.D in chemistry from Harvard University and has 18 years of drug discovery experience with Merck. He has been responsible for the identification of seven development candidates during this time and also led teams responsible for the development of Previcox® and odanacatib, a cathepsin K inhibitor currently in Phase III development.

Dr Black is the author of more than 50 scientific publications and is an inventor on 25 issued patents. Prior to co-founding Kaneq Pharma, he served as Director of Chemistry and Site Scientific Operations Lead at Merck Frosst.

Kaneq Pharma is a discovery and early development stage pharmaceutical company being formed by former employees of the Merck Frosst Center for Therapeutic Research.

The focus of Kaneq Pharma is the delivery of high value molecules for validated targets in the area of metabolic disease.



Thomas Mathers

Chief Executive Officer

CoLucid Pharmaceuticals, Inc

Tom joined CoLucid as Chief Executive Officer in 2011. He has more than nineteen years of executive management experience in the life sciences and medical device industry. Mr. Mathers also serves on the Board of Directors for the Biotechnology Industry Organization (BIO), and as chairman of Déclion Pharmaceuticals, a company which he co-founded.

Prior to CoLucid, Tom served as president and CEO of Peptimmune, Inc.; president and CEO of Cell Based Delivery; vice president and general manager of Cardion AG; vice president of Strategic Development at Genzyme; and management positions at Snowden-Pencer and Pfizer, Inc.

Tom holds several patents and patents pending and earned his BS in Engineering from the United States Military Academy at West Point, where he was a Dean's List student and three-year starter on the football team as a defensive end. From 1988 to 1991 he served as captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War in the XVIII Airborne Corps.

Education

United States Military Academy at West Point
(BS in Engineering)



Gary Muirhead

CEO and Founder

Ixchelsis Ltd

Gary graduated in Applied Biology from Cardiff University in 1979 and then trained and was employed as a Clinical Biochemist at the University Hospital of Wales and Surrey County Hospital through to 1986. Gary then joined Roche as a Team Leader and Senior Scientist, Pharmacokinetics/Drug Metabolism.

In 1993 Gary joined the Pfizer Clinical Pharmacology group in Sandwich and held positions of increasing responsibility over the subsequent 14 years. As well as managing the Clinical Pharmacologists and providing strategic leadership in the GI, GU/Sex Health and Anti-viral therapeutic areas, Gary was also the Global Clinical Pharmacology lead for a number of successful drugs including Viagra, Celsentry[®], and Geodon[®]. Gary also acted as Early Clinical Leader for a number of GU/Sex Health projects during this period. In 2006 Gary was appointed Sandwich Site Head for Clinical Research Operations and successfully built a group responsible for the operational delivery of exploratory development, clinical pharmacology and clinical technology clinical studies.

In June 2009 Gary was appointed to the position of Vice President, Clinical Affairs Site Head for Specialty Care in Sandwich. In this position Gary managed the clinicians, statisticians and clinical pharmacologists, ensuring the provision of quality resources to the Asset Teams.

Gary is now Founder and Chief Executive Officer of Ixchelsis Ltd a Pfizer Sandwich Start-up focusing on developing drugs in Men's Health indications.



TVM | Capital
Winter Conference 2015

4:00pm An Insider Perspective on Russia

Discussion with:

- **Andrei Petrov, INBIO VENTURES**
- **Alexandra Goll, TVM Capital Life Science Munich**
- **Peter Neubeck, TVM Capital Life Science Munich**
- **Hubert Birner, TVM Capital Life Science Montreal and Munich**



Andrei Petrov

Chief Executive Officer, Managing Partner

INBIO VENTURES

Andrei Petrov is a founder of Inbio Ventures - management company for a private venture capital fund Pharmstandard International (Luxembourg). He is a Russian scientist with a vast knowledge and 11 years of experience in molecular biology, cell biology and immunology. He is Member of the Board of Affitech AS (Norway, Denmark), co.don AG (Germany), Argos Therapeutics (USA) and enGene (Canada). Before Inbio Ventures was founded, Dr. Petrov gained extensive experience of 10+ years in biopharmaceutical industry being heavily involved in all aspects of drug discovery and drug development. He served as Chief Scientific Officer of International Biotechnology Center Generium even far before the company was officially incorporated in 2011. His main responsibilities were spread from portfolio building and its comprehensive day-to-day management, including full set of related business development activities, to strategic planning of overall company's development. These activities resulted in evolving of a small start-up company to internationally recognized biopharmaceutical R&D Center with 40+ actively managed projects.



Alexandra Goll

General Partner

TVM Capital Life Science Munich

Dr. Alexandra Goll, who joined TVM Capital in early 1998 has been responsible for more than 20 TVM Capital investments.

She initiated TVM Capital's lead investment in Actelion Ltd (Allschwil, Switzerland) and led the firm's successful investments in Idenix Pharmaceuticals, Inc. sold to Novartis, and Pharmasset Inc. which was sold to Gilead Sciences – TVM Capital acted as a lead investor in both cases. She also initiated and managed the investment in EUSA Pharma Ltd., recently sold to Jazz Pharmaceuticals Inc.

Currently, Dr. Goll serves on the Board of Directors of Albireo (Gothenburg, Sweden), Biovertis AG (Vienna, Austria) and Cerenis Therapeutics (Toulouse, France and Ann Arbor, MI). She also represents the interests of TVM Capital with Addex Pharmaceuticals SA (Geneva, Switzerland) and Newron Pharmaceuticals SpA, (Bresso, Italy).

Prior to her affiliation with TVM Capital, Dr. Goll was the Global Business Leader for HIV and CMV, and was responsible for strategic marketing and business development for Virology at Roche Ltd. in Basel. She had been involved in clinical development and managing commercialization strategies of products such as Neupogen® (under an agreement with Amgen), Hivid®, Cymevene® and Valcyte®. Dr. Goll holds a degree in pharmacy from the Free University of Berlin, and wrote her doctoral dissertation in natural sciences at Philipps University of Marburg. She was also honored with a post-doctoral position supported by the Boehringer-Ingelheim Foundation for fundamental research in medicine.



Peter Neubeck

Venture Partner

TVM Capital Life Science Munich

Dr. Peter Neubeck is currently a Chief Business Officer at Aspireo Pharmaceuticals Ltd. As a venture partner at TVM Capital, he supports deal origination and the evaluation of new investments, as well as research and support for existing portfolio companies with an emphasis on clinical development stage to commercial stage investments, including virtual asset development type investments ('Project-Focused-Companies').

Prior to joining TVM Capital, he worked at Novartis Pharma as Global Project Leader for the Cardiovascular & Metabolism Business Franchise, and was responsible for the life cycle strategy and development of the novel potential blockbuster antihypertensive Rasilez®/Tekturna®, including the recent FDA approval of the first fixed dose combination Tekturna HCT®. Prior to this role he worked as manager in the Pharma Strategic Planning Group focusing on the global disease area strategy of Novartis.

He has completed his medical studies at Ludwig-Maximilian-University München and Harvard Medical School and holds a doctoral degree for his work in non-invasive cardiovascular imaging using electron beam tomography. After pursuing postgraduate training in neurology and internal medicine in Munich, the Cleveland Clinic and Beth Israel Deaconess Medical Center, he obtained an MBA at INSEAD and worked at McKinsey & Company's Zurich office, serving several of the top pharmaceutical companies in turnaround and growth projects.



**5:00pm Panel Discussion:
Life Science Fund of Funds – A perspective of the Investors behind the
Investor**

Panelists:

- **Cedric Bisson**, Teralys Capital
- **Drew R. Smith**, Advantus Capital Management

Moderator: Luc Marengere, TVM Capital Life Science Montreal



Jacques Bernier

Managing Partner

Teralys Capital

Jacques is a highly respected venture capitalist, entrepreneur and investor who's helped shape the Canadian technological innovation scene.

Through a 30 year career of contributions to the high-tech community, he has been actively involved in more than a dozen emerging high-tech companies as Founder/CEO or angel investor as well as Senior Vice-President of the Solidarity Fund QFL.

Jacques' widely valued wisdom and experiences continue to define, develop and implement a new approach to venture capital in Québec and abroad.



Drew R. Smith

Vice President, Sr. Investment Officer

Advantus Capital Management/Securian Financial Group

Drew oversees the deployment of more than \$700 million in alternative assets on behalf of Advantus and its clients. He is charged with sourcing, due diligence, ongoing oversight and the construction of portfolios containing venture capital, buyout, mezzanine debt, distressed debt and infrastructure investments. He also serves as member of the portfolio management team of the Securian Financial Group's \$750 MM retirement plan.

Drew is a member of the CFA Institute, the CFA Society of Minnesota and the CAIA Association. He serves as a member of the advisory board for over one dozen venture, buyout and mezzanine debt funds. Drew graduated from the University of Rochester and earned an MBA from the Thunderbird School of Global Management




TVM | Capital
Winter Conference 2015

Speaker/Moderator Profiles

(In order of appearance)

Thursday, Feb. 12

2:00pm New Ways of Structuring the Innovation Supply Chain in Therapeutics: Discussion and Case Examples



Gary P. Pisano

Harry E. Figgie, Jr. Professor of Business Administration

Harvard Business School

Gary Pisano is the Harry E. Figgie Professor of Business Administration at the Harvard Business School. He has been on the Harvard faculty for 25 years. During this time, his research, teaching, and consulting has focused on technology strategy, the management of innovation, organizational learning, manufacturing and outsourcing strategy, and the management of intellectual property. His work on these issues spans a range of science and technology based industries including aerospace, biotechnology and pharmaceuticals, specialty chemicals, health care, nutrition, computers, software, telecommunications, and semiconductors.

Pisano is the author of over 70 articles and case studies. His "Restoring American Competitiveness" (co-authored with Willy Shih) won the McKinsey Award for best article published in Harvard Business Review in 2009. He is also co-author of the award winning article, "Dynamic Capabilities and Strategic Management" (Strategic Management Journal, 1997), the most-cited publication in economics and business from 1995-2005. His article "How to Capture Value from Innovation: Shaping Intellectual Property and Industry Architecture" (California Management Review) was a finalist for the 2008 Accenture Award. He has also written case studies on such companies as Amazon, BMW, Fiat-Chrysler, IBM, Intel, Jet Blue, Merck, Eli Lilly, Vertex Pharmaceuticals, Teradyne, Flextronics, Virgin Group, and VF Brands. He is the author of six books including The Development Factory; Operations, Strategy, and Technology (with co-authors Robert Hayes, David Upton, and Steve Wheelwright); Science Business: The Promise, The Reality and The Future of Biotech and, most recently, Producing Prosperity: Why America Needs a Manufacturing Renaissance (co-author Willy Shih).



TVM | Capital
Winter Conference 2015

4:00pm Panel discussion - External Innovation in Action

Panelists:

- **Gary Muirhead**, Ixchelsis Ltd
- **Werner Lanthaler**, Evotec AG
- **Gary Pisano**, Harvard Business School
- **Helmut Schühslser**, TVM Capital Healthcare Partners

Moderators: Hubert Birner and Marc Rivière, TVM Capital Life Science



Marc Riviere

General Partner

TVM Capital Life Science Montreal

Marc Rivière joined the Montreal-based TVM Capital team in 2013 after twenty years of international drug development preceded by ten years of medical and public health practice in Europe and the Middle East. An experienced executive with a track record in successfully building and managing clinical programs, Marc's expertise encompasses all aspects of drug development in different clinical indications from pre-clinical development to post marketing surveillance. At TVM Capital, he focuses on evaluation of deal opportunities and investment management for therapeutics. He also works closely with the firm's strategic partner Eli Lilly & Co. and its drug development division Chorus.

Prior to joining TVM Capital, Marc was Vice-President, Axcan Pharma Inc., in charge of Clinical Development, Medical Affairs and Pharmacovigilance and a member of the Axcan Licensing Committee. He also served as Senior Vice President, Clinical Development at Caprion Pharmaceuticals, Chief Medical Officer for Bioniche Life Sciences Inc., Managing Director of Xenon Genetics Inc., Vice President of Clinical Affairs, Aeterna Labs and Executive Vice President and Regional Director, Quintiles Inc. He was also member of the Guideline Review Committee of the Canadian Co-ordination Office of Health Technology Assessment. Marc received his Tropical Disease Medicine Certification from Université Bordeaux II, France and Medicine Doctorate from Université Paul Sabatier, Toulouse, France, and has over fifty publications and scientific communications to his credit.



Werner Lanthaler

Chief Executive Officer

Evotec AG

Dr Werner Lanthaler was appointed Chief Executive Officer of Evotec in March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr Lanthaler played a pivotal role in many of the company's major corporate milestones including the product approval of Intercell's Japanese Encephalitis Vaccine, the company's acquisitions and strategic pharma partnerships, as well as the company's Initial Public Offering in 2005. Previously, from 1998 to 2000 Dr Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company.

He holds a doctorate in economics from Vienna University, earned his Master's degrees from Harvard University and holds a degree in Psychology. In April 2014, Dr Werner Lanthaler became a member of the Supervisory Board of arGEN-X.



TVM | Capital
Winter Conference 2015

5:00pm Panel Discussion

The TVM Capital IPO Party: Giving the Black Swan a Chance

Panelists:

- **Peter Day**, Piper Jaffray & Co.
- **Tim Noyes**, Proteon Therapeutics, Inc.
- **Jeff Abbey**, Argos Therapeutics, Inc.
- **Hendrik Liebers**, Probiodrug AG
- **Stephanie Leouzon**, Torrey Partners Europe

Moderator: Helmut Schüßler, TVM Capital Healthcare Partners



Peter Day

Managing Director

Piper Jaffray & Co

Peter Day is a managing director in biopharma investment banking, having joined Piper Jaffray in 2012. He has more than 14 years experience in biopharma investment banking executing private and public capital raisings, buy- and sell-side mergers, acquisitions and partnership transactions, as well as convertible debt financings.

Prior to Piper Jaffray, Day spent 11 years at Leerink Swann where he was a managing director and one of the earliest members of the investment banking team.

Previously, Day was an investment banker at William Blair & Company focused on mergers and acquisitions. During his career, he has completed more than 50 transactions, including raising over \$2.5 billion in equity capital for life science companies and advising on M&A transactions with an aggregate value of nearly \$5 billion.

Day received a Master of Business Administration degree from the Kellogg Graduate School of Management at Northwestern University and a bachelor's degree from Denison University. Prior to business school, he was a risk management consultant at Aon Risk Services. Day is also a board member and financial officer of the North Suburban YMCA of Boston.



Tim Noyes

President and Chief Executive Officer

Proteon Therapeutics, Inc.

Timothy Noyes joined Proteon in 2006 as our President and Chief Executive Officer and has also been a member of our board of directors since joining the company. From 2002 to 2006, Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., a biopharmaceutical company. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals from 1996 to 2001, prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002, he held the position of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.



Jeff Abbey

President and Chief Executive Officer

Argos Therapeutics, Inc.

Jeffrey D. Abbey has served as the President and Chief Executive Officer and a member of the board of directors of Argos since February 2010. Mr. Abbey served in various other positions at our company from September 2002 to February 2010, including as our Vice President of Business Development from February 2004 to January 2009 and as our Chief Business Officer from January 2009 to February 2010.

Prior to joining Argos, Mr. Abbey served as Vice President of Business Development and Finance at Internet Appliance Network, an information technology company, from 1999 to 2001. Mr. Abbey was a partner at Eilenberg and Krause, LLP, a corporate law firm, from 1994 to 1999. Mr. Abbey received an A.B. in mathematical economics from Brown University and an M.B.A. and J.D. from the University of Virginia.



Hendrik Liebers

Chief Financial Officer

Probiodrug AG

Prior to joining the company as CFO in 2007, Dr Liebers spent nine years with several private equity and venture capital firms with a focus on biotech, pharma, medtech, agro-biotechnology and fund in fund investments. He successfully executed numerous private placements, trade and asset sales, fund in fund investments, mergers and acquisitions as well as licensing and co-development transactions in Europe and the U.S. From 2004 to 2007 he was Head of Life Science at IBG, and was responsible for IBG's Life Science team and activities. From 1998 to 2004 he held several positions with Corporate Finance Holding GmbH (CFH), lastly as Investment Director. Dr Liebers has served on numerous boards, among them as Vice Chairman of Probiodrug's supervisory board until 2007.

He holds a diploma in economics from University of Leipzig, a diploma of biology from Eberhard Karls University of Tuebingen, and a Dr. rer. med. from the Medical Faculty of the University of Leipzig.



Stephanie Leouzon

Partner and Head of Torrey Partners Europe

Torrey Partners Europe

Stephanie Léouzon joined Torrey Partners in 2011 and heads Torrey's European business. Prior to joining Torrey Partners, Stephanie was Managing Director and Senior Advisor of Credit Suisse in London for 12 years, and also worked at Salomon Brothers, JP Morgan and Lehman Brothers in New York. Stephanie has worked on over 100 strategic and financing transactions in the biopharmaceutical industry.

She has advised clients on a number of strategic transactions valued at over \$65 billion, and has been actively involved in financing transactions to provide over \$10 billion to health care clients.



TVM | Capital
Winter Conference 2015

Speaker/Moderator Profiles

(In order of appearance)

Friday, Feb. 13

**. 9:00am Ameco Medical Industries: Public-to-Private Transaction
on the Egyptian NILEX Stock Exchange**



Youssef Haidar

Partner & Managing Director

TVM Capital Healthcare Partners

Youssef Haidar is a Partner and Managing Director of TVM Capital Healthcare Partners. Mr Haidar has been a partner of the firm since it was established in Dubai in 2009 and has made substantial contributions to building the firm's presence in the MENA and India regions. He currently serves as a member of the Investment Committee of the firm in addition to holding board positions with the firm's portfolio companies: ProVita International Medical Center, Cambridge Medical and Rehabilitation Center, Manzil Healthcare Services and Bourn Hall International where he serves as a member of the Audit Committee of the board.

Mr. Haidar brings a wealth of investment and advisory experience from Europe and the wider middle east region. Previously Mr. Haidar was managing director at Unifund Capital Financial Investments in Abu Dhabi, heading the investment banking unit with core market coverage of UAE, Egypt and KSA. Mr. Haidar started his career at Pricewaterhouse Coopers office in Lebanon and London where he was a member of the corporate finance, valuation and strategy and transaction services units of the firm.

Mr. Haidar holds a Master's degree in Finance and Accounting from Kingston University in London (UK) and is a Certified Public Accountant from the State of New Hampshire (USA)

9:45am Update on TVM Capital Healthcare Partners



Helmut M. Schühslers

Chairman & Managing Partner

TVM Capital

Dr. Schuehsler serves as Chairman of the worldwide healthcare activities of TVM Capital Group, Managing Partner of the life science fund generations IV-VI, and Chief Executive Officer of TVM Capital Healthcare Partners Ltd., Dubai, UAE. Since joining TVM Capital in 1990, Dr. Schuehsler has been the deal leader on more than 25 direct investments in life science and healthcare companies in Europe, the U.S., the Middle East and India. In total he has raised more than US\$1bn in committed capital from more than 50 international investors, has overseen more than 80 investments in the health market, and more than 40 IPOs and 20 M&A exit transactions in the portfolio.

In 2007 and 2008, Dr. Schühslers served as chairman of the European Private Equity and Venture Capital Association (EVCA).

Currently he is chairman of healthcare growth companies, ProVita International Medical Center (Abu Dhabi, UAE), Bourn Hall International (Dubai, India), Cambridge Medical and Rehabilitation Center (Abu Dhabi, UAE) and Manzil Health Care Services (Abu Dhabi), as well as director and chairman of the audit committee at U.S. public company, Concert Pharmaceuticals (Lexington, MA, USA). He served as a member of the board of Max-Planck Innovation GmbH for more than 10 years, and was a member of the Selection Committee for the Technology Pioneers program, the Steering Committee of the Entrepreneurship and Successful Growth Research Program of the World Economic Forum in 2009-2012.



TVM | Capital
Winter Conference 2015

10:00am Panel discussion

Partnering Across Borders: Making International Partnerships Work

Panelists:

- **Hoda Abou-Jamra**, TVM Capital Healthcare Partners
- **Joe Henein**, NewBridge Pharma
- **Carl Stanifer**, TVM Capital & Al Faisaliah Group

Moderator: Chad Floe, TVM Capital Healthcare Partners



Charles Floe

**Operating Partner and Managing Director,
Corporate Finance**

TVM Capital Healthcare Partners

Chad joined TVM in October 2014 as an Operating Partner with responsibility for corporate finance and advisory activities with TVM's portfolio companies.

Over a career of more than 27 years in investment banking, Chad built and led international teams of up to 80, focused on healthcare and cross border advisory. He has advised clients in more than 200 M&A, equity, and leveraged finance transactions in Europe, the US and the Middle East, while at HSBC, Dresdner Kleinwort Wasserstein, Lehman Brothers, First Boston and originally at Morgan Bank. An international American now based in Dubai, Chad has been based in London since 1989. Chad's GCC connections are long-standing, having lived in Dubai in 2008 while running HSBC's MENA Advisory business, and covered Saudi Arabia for Morgan Bank in the early 1980s.

Chad has successfully transitioned from an established investment banking career to a plural healthcare industrial career, recently serving as International Director at HCA International (London's leading private hospital group), responsible for evaluating, structuring and negotiating opportunities in the international clinical services space, particularly in the GCC and India.

Chad has also served since 2006 as board member and senior advisor to Ottobock Group GmbH (a private German company and global leader in prostheses and mobility) and on the Executive Committee of the Board of HealthRight International (an international not-for-profit organization providing long-term healthcare solutions in the emerging markets).

He received his MBA (with Distinction) from The Wharton School, and his BA in International Relations from Pomona College.



Hoda Abou-Jamra

Founding Partner

TVM Capital Healthcare Partners

Hoda Abou-Jamra is Founding Partner of TVM Capital Healthcare Partners, the Dubai-based regional healthcare private equity investment operation of TVM Capital, a US\$ 1.8 billion global private equity and venture capital firm. Major responsibilities include fundraising, investor relations, corporate development, and business development for portfolio companies.

Simultaneously, she is the Founder and CEO of the non-profit “think tank” organization The BioExec Institute, Inc., in Cambridge, MA, USA.

Hoda is also the Former CEO of Boston BioCapital, with representations in Cambridge, MA, USA and Dubai, UAE. Boston BioCapital and TVM Capital entered into a joint venture to establish TVM Capital Healthcare Partners.

She has, in recent years, been invited to speak globally on private equity in the Middle East as well as the role of women in business in the Middle East. Hoda has also been featured in articles in the New York Times and in the Gulf region.

Hoda is a current board member of Manzil Health Care Services, a provider of highly individualized home care services for adult and pediatric patients and The BioExec Institute, a non-profit biotech organization. Former board member of Gulf Healthcare International, Dubai, UAE, a regional healthcare services and medical laboratory company. Former manager sales, marketing, and business development for several biotechnology and pharmaceutical companies including Acumen Sciences, Incyte Genomics, Boiron Laboratories, and Bayer Corporation. Former member on several U.S. finance and fundraising committees, including Senator John Kerry’s Campaign Finance Committee, the Massachusetts Women’s Political Caucus and the BIO Business Forum Committee and the International Subcommittee. She graduated from the Bouve College of Health Sciences, Northeastern University, Boston, with a degree in Pharmacy.



Jo Henein

President & Chief Executive Officer

NewBridge Pharmaceuticals FZ LLC

Joe Henein is a senior Pharma executive with a career extending over 30 years in big Pharma, covering many geographies including; USA, Europe, and the Middle East. Formerly, Joe served as the Managing Director of Wyeth Pharmaceuticals for the Middle East and North Africa (MENA), VP Strategic Marketing and Global Commercial Chair for a number of therapeutic areas, most notably infectious diseases, and the Therapeutic Area Head for Women's Health Care.

He has also assumed a number of senior managerial roles in American Cyanamid and Merrill Dow and served in various corporate and industry committees; including PhRMA MEAC as the Vice Chair and the Chair for the PhRMA MEAC Ethics Review Board. Joe is a frequent speaker in pharmaceutical congresses including compliance forums. Joe holds a PharmD. Degree.



Carl Stanifer

Senior Advisor

TVM Capital Healthcare Partners

Carl Stanifer joined TVM Capital Healthcare Partners in 2014. He resides in Abu Dhabi and works independently, serving as board member and strategic advisor to several health care companies in the Middle East.

He also serves as a member of the board to Cambridge Medical & Rehabilitation Center. Additionally, Mr. Stanifer is Non-Executive Chairman of Arabian International Healthcare Holding Co. (“Tibbiyah”), a wholly owned subsidiary of the Al Faisaliah Group in Riyadh, Saudi Arabia. He has extensive experience in health care operations, financial management, acquisitions, new company start-ups, and new facility development; and successfully served as CEO of Abu Dhabi Health Services Company (“SEHA”) for seven years from August 2007. He was the first CEO of this company following its formation by Emiri Decree in 2007. SEHA owns and operates a multi-facility healthcare company in Abu Dhabi. Prior to joining SEHA, he was Group Chief Financial Officer, Bumrungrad Hospital Public Company Limited in Bangkok, Thailand. Prior to joining Bumrungrad, Mr. Stanifer was Chairman and President of start-up VISTA Healthcare Asia Pte. Ltd., in Singapore. For several years prior to VISTA, he worked for U.S.-based Tenet Healthcare Corporation where he held several senior positions including Senior Vice President, Operations of their International Healthcare Division. During his fifteen-year tenure with Tenet, he lived and worked in Saudi Arabia, Australia, Malaysia and Singapore. He also served in the International Division of Hospital Corporation of America (“HCA”) where he worked with the Singapore Ministry of Health to implement restructuring of MOH hospitals from civil service to private ownership. Prior to 1982, when he began his global healthcare career, he worked with several U.S. based healthcare companies, beginning in 1970 upon completion of undergraduate studies. Mr. Stanifer holds a Bachelor’s Degree in

Accounting and Finance from the University of the Cumberland, and conducted graduate studies in Health Planning and Administration at the University of Cincinnati. He is a past member of the American College of Healthcare Executives and a past member of the U.S. based Healthcare Financial Management Association and the Medical Group Management Association. Mr. Stanifer is a citizen of the USA.